Pharmacists in Markham, IL Accepting Medicare
3 Pharmacists found. Showing 1 - 3
 Pamuela Branch, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3148 W 159th St, Markham, IL 60428 Phone: 708-339-1184 |
 Dr. Onyango Nono, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15940 Kedzie Ave, Markham, IL 60428 Phone: 708-339-1184 |
Mr. Carl Schmook Iii Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3148 W 159th St, Markham, IL 60428 Phone: 708-339-1184 |
News Archive
Scientists uncover bacterial secretion system that allows sharing of genetic material between bacteria
The system that allows the sharing of genetic material between bacteria - and therefore the spread of antibiotic resistance - has been uncovered by a team of scientists at Birkbeck, University of London and UCL.
Medical Research Council funds research to look at cannabis based medicines in multiple sclerosis treatment
A trial to determine whether cannabis-based medicines can reduce disability in patients with multiple sclerosis (MS) has been funded by the Medical Research Council (MRC).
Silence Therapeutics receives patent for RNA silencing method
Silence Therapeutics plc announces the issuance of United States patent 7,772,203, titled "Methods and Compositions for Controlling Efficacy of RNA Silencing," by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of enhancing RNA silencing with a double stranded RNA interference (RNAi) agent. The patent's RNA silencing method claims include coverage for the administering of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin (shRNA) molecules. Silence believes the proprietary structural modification techniques covered in this patent will play a key role in increasing the potential therapeutic efficacy of RNAi therapeutics.
Precision Therapeutics' ChemoFx test feasible in cervical cancer
Precision Therapeutics announces the acceptance of a new abstract on the ChemoFx® in vitro drug response marker for publication in conjunction with the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
Ampio finalizes negotiations to acquire DMI BioSciences
Ampio Pharmaceuticals, Inc. today announced it has finalized negotiations with the directors of DMI BioSciences, Inc. (DMI) to acquire DMI BioSciences, Inc. This acquisition will give Ampio access to all rights, royalties and patents associated with DMI's major assets, drugs for male sexual dysfunction including premature ejaculation (PE) and combination drugs to treat premature ejaculation and erectile dysfunction (ED).
› Verified 8 days ago
Counselors
Pharmacists
Clinical Social Workers
Dentists
Occupational Therapists